A device that measures blood glucose through closed eyelids using acoustic waves. Less than ten seconds. No consumables. A scientifically documented method — now made possible by near-molecular precision.
Test blood sugar — without needles, without blood, without pain. Offner Technologies is developing a device that measures blood glucose through closed eyelids using acoustic waves. The device sends an acoustic wave into the eye's vitreous humor — a homogeneous fluid chamber of approximately 16 mm — and measures its transit time with extraordinary precision, resolving differences of approximately 10 picoseconds. The relationship between glucose concentration and acoustic wave speed in ocular fluid is well documented in scientific literature. This is a direct measurement, not an estimate — in less than ten seconds.
More than 537 million adults worldwide live with diabetes. Millions of them must test their blood glucose multiple times a day — each time pricking a finger or wearing a sensor embedded under the skin. For children, the elderly, and people with needle anxiety, this is not merely inconvenient — it is a daily source of suffering and a barrier to proper glucose management.
The standard for decades. Painful, requires consumable strips, produces medical waste. Compliance drops when patients must test 4–8 times daily.
A major improvement — but still requires a sensor inserted under the skin, replaced every 7–14 days. Expensive, sometimes inaccurate, and causes skin irritation for many users.
Decades of attempts using infrared, Raman spectroscopy, radio waves, and sweat analysis. None has achieved the precision required for clinical glucose measurement. The challenge has occupied leading experts for years.
The theoretical solutions have been known for years. There is scientific evidence that direct glucose measurement is possible in the eye's fluid. The vitreous humor — the gel-like fluid filling the eye — is a nearly ideal measurement medium: homogeneous, acoustically transparent, and its glucose concentration directly correlates with blood glucose levels.
The mathematical relationship is well documented: as glucose concentration changes, the speed of acoustic wave propagation through the ocular fluid changes in a predictable, measurable way. This is not an indirect proxy or an estimate — it is a direct measurement.
The science has been known. The problem has been the lack of non-invasive equipment with the required precision. The glucose-induced change in acoustic wave transit time is extremely small — on the order of picoseconds. No existing non-invasive device could resolve differences this small. Until now.
The patient simply closes their eyes. No preparation, no contact lenses, no drops.
A harmless acoustic wave passes through the closed eyelid into the vitreous humor — approximately 16 mm of homogeneous fluid.
The NL-SWI platform measures the wave's transit time with ~10 picosecond resolution — detecting glucose-related speed changes.
The mathematically documented relationship between transit speed and glucose concentration yields a direct reading. Less than ten seconds.
The entire measurement is non-invasive, painless, and requires no consumables. The precision derives from the NL-SWI platform's core capability — decoupling measurement precision from wave frequency — which enables near-molecular accuracy at any frequency.
| Feature | Finger Prick | CGM | NL-SWI |
|---|---|---|---|
| Invasive | Yes — blood draw | Sensor under skin | No — closed eyelid |
| Pain | Every test | At insertion | None |
| Consumables | Test strips | Sensors (7–14 days) | None |
| Measurement Type | Direct (blood) | Interstitial (delayed) | Direct (ocular fluid) |
| Measurement Time | ~5 seconds | Continuous | <10 seconds |
| Skin Irritation | Calluses | Common | None |
| Medical Waste | Yes | Yes | None |
The global glucose monitoring market is projected to exceed $30 billion by 2030, driven by the growing diabetes epidemic and increasing demand for painless, non-invasive solutions.
The compliance problem — patients who should test 4–8 times daily often test only 1–2 times because of pain and inconvenience. Non-invasive measurement removes the primary barrier to proper glucose management.
The precision gap — every previous non-invasive attempt has failed to achieve clinical-grade precision. The NL-SWI platform's ability to resolve transit-time differences of approximately 10 picoseconds represents a fundamentally different level of measurement capability.
The consumables burden — finger-prick testing and CGM systems require ongoing purchases of test strips and sensors. A device with no consumables transforms the economics of glucose monitoring for patients and healthcare systems alike.
Offner Technologies is looking for a strategic partner with expertise in endocrinology, diabetes care, or glucose monitoring — who can take a validated measurement platform and turn it into a product that transforms the lives of hundreds of millions of people.
Start a Conversation →